https://www.selleckchem.com/products/MDV3100.html
This study provides an experimental basis for the development of a new configuration of BA for the treatment of cancer.Oncolytic virotherapy is a promising therapeutic approach for the treatment of cancer. TG6002 is a recombinant oncolytic vaccinia virus deleted in the thymidine kinase and ribonucleotide reductase genes and armed with the suicide gene FCU1, which encodes a bifunctional chimeric protein that efficiently catalyzes the direct conversion of the nontoxic 5-fluorocytosine into the toxic metabolite 5-fluorouracil. In translati
Curtir
Comentario
Compartilhar
